- Home
- UFPI vs JAZZ Comparison
UFPI vs JAZZ Comparison
Compare UFPI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFPI
- JAZZ
- Stock Information
- Founded
- UFPI 1955
- JAZZ 2003
- Country
- UFPI United States
- JAZZ Ireland
- Employees
- UFPI N/A
- JAZZ N/A
- Industry
- UFPI Forest Products
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- UFPI Basic Materials
- JAZZ Health Care
- Exchange
- UFPI Nasdaq
- JAZZ Nasdaq
- Market Cap
- UFPI 6.2B
- JAZZ 7.3B
- IPO Year
- UFPI 1993
- JAZZ 2007
- Fundamental
- Price
- UFPI $97.56
- JAZZ $108.07
- Analyst Decision
- UFPI Strong Buy
- JAZZ Strong Buy
- Analyst Count
- UFPI 4
- JAZZ 13
- Target Price
- UFPI $143.00
- JAZZ $181.85
- AVG Volume (30 Days)
- UFPI 490.7K
- JAZZ 1.3M
- Earning Date
- UFPI 04-28-2025
- JAZZ 05-06-2025
- Dividend Yield
- UFPI 1.44%
- JAZZ N/A
- EPS Growth
- UFPI N/A
- JAZZ 49.21
- EPS
- UFPI 6.11
- JAZZ 7.51
- Revenue
- UFPI $6,608,862,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- UFPI $0.88
- JAZZ $5.92
- Revenue Next Year
- UFPI $4.65
- JAZZ $4.22
- P/E Ratio
- UFPI $15.97
- JAZZ $14.39
- Revenue Growth
- UFPI N/A
- JAZZ 5.76
- 52 Week Low
- UFPI $95.90
- JAZZ $95.49
- 52 Week High
- UFPI $141.33
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- UFPI 43.03
- JAZZ 47.97
- Support Level
- UFPI $96.99
- JAZZ $106.69
- Resistance Level
- UFPI $99.71
- JAZZ $110.48
- Average True Range (ATR)
- UFPI 2.00
- JAZZ 3.56
- MACD
- UFPI -0.07
- JAZZ 0.55
- Stochastic Oscillator
- UFPI 18.46
- JAZZ 68.77
About UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.